Skip to content

Enliven 制药

US · ELVN #2416 按市值排名 上市于 1970
37.32 -2.01 -5.11%
实时 - 追踪5344个代码 - 心跳于230秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

增持
  • 最近一期（2026/Q3）披露持股的机构数量增加了4家。
  • 机构持股总比例上升了0.3个百分点。

机构持股

机构持股比例
112.07% +0.32pp
机构数量
250 +4
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund60.48%
Hedge Fund32.86%
VC/PE Fund14.54%
Individual/Insider2.69%
Sovereign Wealth Fund1.89%
Public Company1.40%
Insurance Company0.40%
Government Pension Fund0.29%
Private Company0.16%

主要股东 截至 2026-06-30

FMR 13.68% · 10.03M 股
OrbiMed Advisors LLC 9.25% · 6.78M 股
Polar Capital Holdings Plc 8.78% · 6.43M 股
BlackRock 5.95% · 4.36M 股
Vestal Point Capital, LP 5.46% · 4.00M 股
Commodore Capital LP 4.47% · 3.28M 股
T. Rowe Price Group, Inc. 4.37% · 3.20M 股
Vanguard Capital Management, LLC 4.03% · 2.95M 股
Citadel Advisors LLC 2.82% · 2.07M 股
Fairmount Funds Management LLC 2.53% · 1.86M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 15次买入 · 35次卖出

姓名职务持股比例
Joseph Lyssikatos Co-Founder, Chief Scientific Officer & Directors 1.01%
Samuel Kintz Co-Founder, CEO, Secretary & Director 0.89%
Anish Patel Co-Founder & COO 0.29%
Richard Heyman Independent Chairperson 0.23%
Jacob Bauer Independent Director 0.12%
Lori Kunkel Director 0.06%
Helen Collins Chief Medical Officer 0.03%
Rahul Ballal Director 0.03%
Benjamin Hohl CFO & Head of Corporate Development 0.02%
OrbiMed Advisors LLC -- --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Scott Garland Director Derivative Exercise and Sale -13,000 $15.47–46.67
2026-09-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–51.48
2026-09-16 Benjamin Hohl CFO & Head of Corporate Development Open Market Disposition -2,036 $50.72–51.49
2026-09-16 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -3,982 $14.85–50.72
2026-09-03 Richard Heyman Independent Chairperson Intent to Sell (Form 144) -38,000 $59.29
2026-08-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–59.35
2026-08-16 Benjamin Hohl CFO & Head of Corporate Development Automatic Disposition -6,018 $58.35–59.35
2026-08-03 Mika Derynck Independent Director Derivative Exercise and Sale -158,795 $2.48–60.21
2026-07-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–53.92
2026-07-16 Benjamin Hohl CFO & Head of Corporate Development Automatic Disposition -4,946 $52.32–53.87
2026-07-16 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -1,072 $2.48–52.32
2026-07-05 Lori Kunkel Director Automatic Disposition -10,000 $49.98–50.84
2026-06-21 OrbiMed Advisors LLC -- Private Disposition -48,253 $45.00
2026-06-21 OrbiMed Advisors LLC -- Open Market Disposition -811,870 $45.38
2026-06-16 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–44.74
2026-06-16 Benjamin Hohl CFO & Head of Corporate Development Derivative Exercise and Sale -6,018 $2.48–44.75
2026-06-14 OrbiMed Advisors LLC -- Open Market Disposition -281,408 $45.02
2026-06-04 Lori Kunkel Director Automatic Disposition -10,000 $34.28–35.82
2026-05-17 Helen Collins Chief Medical Officer Derivative Exercise and Sale -5,000 $2.48–41.21
2026-04-29 Joseph Lyssikatos Co-Founder, Chief Scientific Officer & Directors Intent to Sell (Form 144) -25,000 $42.40

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Enliven 制药 讨论区 0 条评论

发表评论